Fundraising Fox
Bambusa Therapeutics
Austin, US · Founded 2024 · Delaware corporation · 6 known investors
Find your way into Bambusa Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Derek DiRocco to introduce you to Crystal MacKay
You →Derek · together at Bambusa Therapeutics →Crystal
Ask Jamie Chen to introduce you to Helmut Jeggle
You →Jamie · together at Bambusa Therapeutics →Helmut
Sign up to find every way you can get introduced to Bambusa Therapeutics
- Your email: who you already know at Bambusa Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Bambusa Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.
Founders & leadership
Bambusa Therapeutics was founded in 2024 by Shanshan Xu and Helmut Jeggle.
Investors · 6
How we know: INCE Capital's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us
How we know: RA Capital's portfolio page · the company's own site · board seat on SEC Form D · funding news · Not right? Tell us
How we know: the company's own site · Salvia's portfolio page · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$67.4M disclosed across 3 rounds · 2024–2025
▶$53.3MraisedFeb 2025 · 16 investors · BiotechnologyRule 506(b)
- Sean MarettDirector
- Helmut JeggleDirector
- Derek DiRoccoDirector
- Shanshan XuExecutive Officer, Director, Promoter
- Offering amount
- $88.9M
- Amount sold
- $53.3M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$5.1MraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
- Shanshan XuExecutive Officer, Director, Promoter
- Helmut JeggleDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$9MraisedJan 2025 · 9 investors · BiotechnologyRule 506(b)
- Helmut JeggleDirector
- Shanshan XuExecutive Officer, Director, Promoter
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Bambusa Therapeutics.
In the news
Frequently asked questions
- What does Bambusa Therapeutics do?
- Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.
- Who founded Bambusa Therapeutics?
- Bambusa Therapeutics was founded by Shanshan Xu, Helmut Jeggle in 2024.
- Who are Bambusa Therapeutics's investors?
- Bambusa Therapeutics's investors include INCE Capital, RA Capital, Salvia, Biotechnology Value Fund, Janus Henderson Investors, REDMILE.
- How much funding has Bambusa Therapeutics raised?
- Bambusa Therapeutics has disclosed $67.4M raised across 3 rounds.
- Where is Bambusa Therapeutics headquartered?
- Bambusa Therapeutics is headquartered in Austin, US.